Cargando…
Clinical Impact of Post-progression Survival in Patients with Locally Advanced Non-small Cell Lung Cancer After Chemoradiotherapy
BACKGROUND: The efficacy of first-line chemoradiotherapy for overall survival (OS) might be confounded by the subsequent treatments in patients with locally advanced non-small cell lung cancer (NSCLC). In this study, we assessed the associations of progression-free survival (PFS) and post-progressio...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Sciendo
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9122299/ https://www.ncbi.nlm.nih.gov/pubmed/35218691 http://dx.doi.org/10.2478/raon-2022-0006 |
_version_ | 1784711315832438784 |
---|---|
author | Imai, Hisao Kobayashi, Daijiro Kaira, Kyoichi Kawashima, Sayaka Masubuchi, Ken Murata, Masumi Ebara, Takeshi Kitamoto, Yoshizumi Minato, Koichi |
author_facet | Imai, Hisao Kobayashi, Daijiro Kaira, Kyoichi Kawashima, Sayaka Masubuchi, Ken Murata, Masumi Ebara, Takeshi Kitamoto, Yoshizumi Minato, Koichi |
author_sort | Imai, Hisao |
collection | PubMed |
description | BACKGROUND: The efficacy of first-line chemoradiotherapy for overall survival (OS) might be confounded by the subsequent treatments in patients with locally advanced non-small cell lung cancer (NSCLC). In this study, we assessed the associations of progression-free survival (PFS) and post-progression survival (PPS) with OS after chemoradiotherapy for locally advanced NSCLC using patient-level data. PATIENTS AND METHODS: Between January 2011 and December 2018, 45 patients with locally advanced NSCLC who had received first-line chemoradiotherapy and in whom recurrence occurred were analysed. The associations of PFS and PPS with OS were analysed at the individual level. RESULTS: Linear regression and Spearman rank correlation analyses revealed that PPS was strongly correlated with OS (r = 0.72, p < 0.05, R2 = 0.54), whereas PFS was moderately correlated with OS (r = 0.58, p < 0.05, R(2) = 0.34). The Glasgow prognostic score and liver metastases at recurrence were significantly associated with PPS (p < 0.001). CONCLUSIONS: The current analysis of individual-level data of patients treated with first-line chemoradiotherapy implied that PPS had a higher impact on OS than PFS in patients with locally advanced NSCLC. Additionally, current perceptions indicate that treatment beyond progression after first-line chemoradiotherapy might strongly affect OS. |
format | Online Article Text |
id | pubmed-9122299 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Sciendo |
record_format | MEDLINE/PubMed |
spelling | pubmed-91222992022-06-01 Clinical Impact of Post-progression Survival in Patients with Locally Advanced Non-small Cell Lung Cancer After Chemoradiotherapy Imai, Hisao Kobayashi, Daijiro Kaira, Kyoichi Kawashima, Sayaka Masubuchi, Ken Murata, Masumi Ebara, Takeshi Kitamoto, Yoshizumi Minato, Koichi Radiol Oncol Research Article BACKGROUND: The efficacy of first-line chemoradiotherapy for overall survival (OS) might be confounded by the subsequent treatments in patients with locally advanced non-small cell lung cancer (NSCLC). In this study, we assessed the associations of progression-free survival (PFS) and post-progression survival (PPS) with OS after chemoradiotherapy for locally advanced NSCLC using patient-level data. PATIENTS AND METHODS: Between January 2011 and December 2018, 45 patients with locally advanced NSCLC who had received first-line chemoradiotherapy and in whom recurrence occurred were analysed. The associations of PFS and PPS with OS were analysed at the individual level. RESULTS: Linear regression and Spearman rank correlation analyses revealed that PPS was strongly correlated with OS (r = 0.72, p < 0.05, R2 = 0.54), whereas PFS was moderately correlated with OS (r = 0.58, p < 0.05, R(2) = 0.34). The Glasgow prognostic score and liver metastases at recurrence were significantly associated with PPS (p < 0.001). CONCLUSIONS: The current analysis of individual-level data of patients treated with first-line chemoradiotherapy implied that PPS had a higher impact on OS than PFS in patients with locally advanced NSCLC. Additionally, current perceptions indicate that treatment beyond progression after first-line chemoradiotherapy might strongly affect OS. Sciendo 2022-02-25 /pmc/articles/PMC9122299/ /pubmed/35218691 http://dx.doi.org/10.2478/raon-2022-0006 Text en © 2022 Hisao Imai, Daijiro Kobayashi, Kyoichi Kaira, Sayaka Kawashima, Ken Masubuchi, Masumi Murata, Takeshi Ebara, Yoshizumi Kitamoto, Koichi Minato, published by Sciendo https://creativecommons.org/licenses/by-nc-nd/4.0/This work is licensed under the Creative Commons Attribution 4.0 International License. |
spellingShingle | Research Article Imai, Hisao Kobayashi, Daijiro Kaira, Kyoichi Kawashima, Sayaka Masubuchi, Ken Murata, Masumi Ebara, Takeshi Kitamoto, Yoshizumi Minato, Koichi Clinical Impact of Post-progression Survival in Patients with Locally Advanced Non-small Cell Lung Cancer After Chemoradiotherapy |
title | Clinical Impact of Post-progression Survival in Patients with Locally Advanced Non-small Cell Lung Cancer After Chemoradiotherapy |
title_full | Clinical Impact of Post-progression Survival in Patients with Locally Advanced Non-small Cell Lung Cancer After Chemoradiotherapy |
title_fullStr | Clinical Impact of Post-progression Survival in Patients with Locally Advanced Non-small Cell Lung Cancer After Chemoradiotherapy |
title_full_unstemmed | Clinical Impact of Post-progression Survival in Patients with Locally Advanced Non-small Cell Lung Cancer After Chemoradiotherapy |
title_short | Clinical Impact of Post-progression Survival in Patients with Locally Advanced Non-small Cell Lung Cancer After Chemoradiotherapy |
title_sort | clinical impact of post-progression survival in patients with locally advanced non-small cell lung cancer after chemoradiotherapy |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9122299/ https://www.ncbi.nlm.nih.gov/pubmed/35218691 http://dx.doi.org/10.2478/raon-2022-0006 |
work_keys_str_mv | AT imaihisao clinicalimpactofpostprogressionsurvivalinpatientswithlocallyadvancednonsmallcelllungcancerafterchemoradiotherapy AT kobayashidaijiro clinicalimpactofpostprogressionsurvivalinpatientswithlocallyadvancednonsmallcelllungcancerafterchemoradiotherapy AT kairakyoichi clinicalimpactofpostprogressionsurvivalinpatientswithlocallyadvancednonsmallcelllungcancerafterchemoradiotherapy AT kawashimasayaka clinicalimpactofpostprogressionsurvivalinpatientswithlocallyadvancednonsmallcelllungcancerafterchemoradiotherapy AT masubuchiken clinicalimpactofpostprogressionsurvivalinpatientswithlocallyadvancednonsmallcelllungcancerafterchemoradiotherapy AT muratamasumi clinicalimpactofpostprogressionsurvivalinpatientswithlocallyadvancednonsmallcelllungcancerafterchemoradiotherapy AT ebaratakeshi clinicalimpactofpostprogressionsurvivalinpatientswithlocallyadvancednonsmallcelllungcancerafterchemoradiotherapy AT kitamotoyoshizumi clinicalimpactofpostprogressionsurvivalinpatientswithlocallyadvancednonsmallcelllungcancerafterchemoradiotherapy AT minatokoichi clinicalimpactofpostprogressionsurvivalinpatientswithlocallyadvancednonsmallcelllungcancerafterchemoradiotherapy |